NOVASN68 Price

NOVA, developed by Metanova Labs - crypto-native biotech company, operates as Bittensor Subnet 68, creating the world's first decentralized, open platform for high-throughput virtual drug screening and early-stage discovery.

Miners submit batches of candidate molecules drawn from vast libraries like SAVI 2020, proposing structures optimized for specific protein targets. Validators use deterministic, GNN-based oracles (such as PSICHIC) to score submissions on binding affinity, potency, target vs. anti-target differentials, structural novelty and other metrics, enforcing rules like duplicate invalidation and decaying bonuses for early diversity.

The subnet targets mental health therapeutics and other areas, with low hardware entry for broad participation, and aims to license discoveries for real-world impact while building recurring value through the network.